 cardiorepar effect lisinopril rat genet hypertens ventricular hypertrophi background genet hypertens structur remodel nonmyocyt compart myocardium accumul fibrillar collagen interstitium adventitia intramyocardi coronari arteri medial thicken vessel determin patholog hypertrophi ventricular dysfunct method result benefit angiotensin enzym inhibit interstiti vascular remodel rat genet spontan hypertens shr ventricular hypertrophi lvh male shr oral lisinopril averag dose mg/kg/day week myocardi stiff coronari vascular reserv micrograms/min isol heart myocardi collagen intramur coronari arteri architectur lisinopril-tr shr baselin untreat shr age- sex-match wistar-kyoto wki control regress lvh normal blood pressur complet regress interstiti fibrosi decreas interstiti collagen volum fraction wki normal myocardi stiff constant wki revers intramur coronari arteri remodel decreas ratio perivascular fibrosi lumen size wki medial thicken micron wki micron restor coronari vasodil respons ml/min/g wki ml/min/g shr lvh advers structur remodel cardiac interstitium lisinopril fibrou tissu accumul medial thicken intramyocardi coronari arteri myocardi stiff coronari vascular reserv normal conclus cardiorepar properti angiotensin enzym inhibit valuabl ventricular dysfunct hypertens heart diseas